Ceftolozane/Tazobactam treatment for patients with hospital-acquired and ventilatory-associated bacterial pneumonia in Canada in 2022-2024: results from the CLEAR registry.

Autor:	Zhanel GG; Department of Medical Microbiology and Infectious Diseases, Max Rady College of Medicine, University of Manitoba, Winnipeg, Manitoba, Canada., Dhami R; Department of Pharmacy, London Health Sciences Centre, London, Ontario, Canada., Baxter M; Department of Medical Microbiology and Infectious Diseases, Max Rady College of Medicine, University of Manitoba, Winnipeg, Manitoba, Canada., Wong M; Department of Pharmacy, Fraser Health, Vancouver, British Columbia, Canada., Mirzanejad Y; Department of Medicine, University of British Columbia, Vancouver, British Columbia, Canada., Kosar J; Department of Pharmacy, Royal University Hospital, Saskatoon, Saskatchewan, Canada., Cervera C; Division of Infectious Diseases, Faculty of Medicine, University of Alberta, Edmonton, Alberta, Canada., Irfan N; Department of Pharmacy, Hamilton Health Sciences Centre, Hamilton, Ontario, Canada., Borgia S; Section of Infectious Diseases, William Osler Health System, Brampton, Ontario, Canada., Serebryanskyy A; Department of Pharmacy, London Health Sciences Centre, London, Ontario, Canada., Ariano R; Department of Pharmacy, St. Boniface General Hospital, Winnipeg, Manitoba, Canada., Savoie M; Department of Pharmacy, CIUSSS de l'Est-de-l'Île-de-Montréal, Montreal, Quebec, Canada., Tascini C; Infectious Diseases Clinic, DAME, Udine University Hospital, Udine, Italy., Walkty A; Department of Medical Microbiology and Infectious Diseases, Max Rady College of Medicine, University of Manitoba, Winnipeg, Manitoba, Canada., Karlowsky JA; Department of Medical Microbiology and Infectious Diseases, Max Rady College of Medicine, University of Manitoba, Winnipeg, Manitoba, Canada.
Jazyk:	angličtina
Zdroj:	Expert review of anti-infective therapy [Expert Rev Anti Infect Ther] 2024 Sep 26, pp. 1-8. Date of Electronic Publication: 2024 Sep 26.
DOI:	10.1080/14787210.2024.2405930
Abstrakt:	Background: We report results from the national CLEAR (Canadian Leadership on Antimicrobial Real-Life Usage) registry on the usage of ceftolozane/tazobactam in Canada from 2022 to 2024. Research Design and Methods: The authors reviewed the final data using the national ethics approved CLEAR study. Thereafter, the literature is surveyed regarding the usage of ceftolozane/tazobactam to treat patients with HABP and VABP via PubMed (up to May 2024). Results: Ceftolozane/tazobactam was primarily used as directed therapy to treat HABP and VABP caused by Pseudomonas aeruginosa . It was primarily used alone, or in combination with another agent, to treat resistant and multidrug-resistant (MDR) P. aeruginosa infections. Despite primarily being used to treat severely ill patients in intensive care units, its use was associated with relatively high microbiological/clinical cure rates, along with an excellent safety profile. Several reports attest to the microbiological/clinical efficacy and safety of using ceftolozane/tazobactam to treat HABP and VABP. Conclusions: In Canada, ceftolozane/tazobactam is primarily used as directed therapy alone, or in combination, to treat MDR P. aeruginosa infections. Though mostly used to treat severely ill patients in the ICU, ceftolozane/tazobactam use in HABP and VABP is associated with relatively high microbiological/clinical cure rates and an excellent safety profile.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu